New treatments for ALS are only possible because of the people who participate in and conduct clinical trials. As the number of ALS trials continues to increase, the number of people with ALS who enroll in studies and the capacity of trial sites will need to increase as well.
Currently, many people living with ALS who want to participate in clinical trials are unaware of opportunities or lack access to local trial sites. In addition, many trial sites do not have the infrastructure to accommodate significantly more participants and/or additional trial protocols.
Our Trial Capacity Awards provide up to $400,000 over 4 years to help eliminate barriers to trial participation, especially those impacting currently underserved populations, and help increase the number and diversity of people living with ALS who have the opportunity to participate. These awards also support efforts to improve speed and efficiency at both established and emerging clinical trial sites across the U.S.